Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review.
about
THERAPIES FOR CROHN'S DISEASE: a clinical updateAdalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Tumor necrosis factor-α signaling in macrophages.Treatment of pediatric refractory Crohn's disease with thalidomide.Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.Time of infliximab therapy initiation and dose escalation in Crohn's disease.Use of biological molecules in the treatment of inflammatory bowel disease.Review article: remission rates achievable by current therapies for inflammatory bowel disease.Immunopathological characteristics of cryptoglandular and Crohn's anorectal fistulas.Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice.The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.Influence of extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model.
P2860
Q28070271-F29593A1-09BF-4142-8A43-F9A4484C21CDQ30679247-D6340F2E-7B86-4682-9718-021083134737Q34734335-4C065BF0-C5F4-4AB4-AF78-9A3361930A78Q34744824-8DE86DA2-81D8-426A-9DF8-D2061F594941Q35842876-2C34FC81-7EAF-4E25-A036-B19D9BA4697DQ36223905-4EAECC0B-C564-4BF6-A30A-90B390ED8E14Q37454462-8E28706E-5497-46DC-8274-DB2CD5F3E545Q37829470-0E2C9AFA-E9F6-456E-BF24-16BDF531FF9AQ37842605-FC35752C-2A08-4E60-B591-CD439C50E8BDQ37861167-31204536-F9E6-4CC8-AE1A-7D4936CF6FB8Q37947158-034FA37C-47DF-4AEB-B992-7E0B3162E180Q38004932-384D388F-2B66-427B-8E4F-8224DC50A6B7Q38293802-D8A5213D-0418-4DF2-96D9-DC148791222DQ38609128-61CACA4E-BF97-4DF4-8CDB-5E0EF900D1BCQ40327479-3708A627-7CED-49CE-8568-A1D8EDD3F25FQ46846798-8FA4C489-9682-481C-A111-203D6929730FQ50526241-84B151AB-4A71-4381-B83A-6A987D9BC786Q54564962-469AEE1F-740E-4CFA-8C51-07F97FC7A11D
P2860
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@ast
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@en
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@nl
type
label
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@ast
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@en
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@nl
prefLabel
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@ast
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@en
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@nl
P1433
P1476
Efficacy of TNF antagonists be ...... diseases: a systematic review.
@en
P2093
Silvio Danese
P304
P356
10.2174/138945010790309939
P577
2010-02-01T00:00:00Z